Skip to main content
SpringerLink
Log in

Adalimumab/infliximab/vedolizumab

Various toxicities and lack of efficacy: 4 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Ayoub A, et al. Safety of Biologic Therapy in Octogenarians and Nonagenarians With Inflammatory Bowel Disease in Ontario: A Case Series. Inflammatory Bowel Diseases 26: e157-e158, No. 12, Dec 2020. Available from: URL: http://doi.org/10.1093/ibd/izaa182

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adalimumab/infliximab/vedolizumab. Reactions Weekly 1888, 20 (2022). https://doi.org/10.1007/s40278-022-08362-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-08362-7

Search

Navigation